Clinical Trials Logo

Clinical Trial Summary

Phase II, open-label, multicentre national study. Patients with metastatic neuroendocrine carcinomas of extrapulmonary origin will be eligible. Treatment will be performed as indicated in the section "Investigational drug and reference therapy". Cisplatinum and everolimus dosing is based upon earlier phase 1 studies (Fury et al. 2012). CTs will be done at 9 weekly intervals (after 3 courses of chemotherapy;). Patients will be treated until documented progression according to RECIST 1.1. Enrolment is expected to take between 14 - 16 months. The total study duration is estimated to be 2 to 3 years until publication. Three NET centres in The Netherlands will participate, (Erasmus Medical Center in Rotterdam, Netherlands Cancer Institute in Amsterdam and , the University Medical Center of Groningen) A pre-treatment (and optional post-treatment) tumour biopsy will be included for DNA/RNA analyses and organoid culture. An additional 5cc of blood will be withdrawn as a germline DNA reference. A second 5 cc of blood will be included for measuring circulating tumour transcripts to identify all types of GEP-NET (NETTest).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02695459
Study type Interventional
Source The Netherlands Cancer Institute
Contact
Status Active, not recruiting
Phase Phase 2
Start date March 30, 2016
Completion date August 2021

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02820857 - Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer Phase 2
Recruiting NCT06041516 - Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas Phase 1
Completed NCT02457273 - Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients Phase 2
Completed NCT04122911 - Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas Phase 2
Recruiting NCT01203306 - Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors Phase 2
Suspended NCT05337735 - A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers Phase 2